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Summary
A rare germ-line polymorphism in codon 47 of the pS3 gene replaces the wild-type proline (CCG) with a serine
(TCG). Restriction analysis of 101 human samples revealed the frequency of the rare allele to be 0% (n = 69)
in Caucasians and 4.7% (3/64, n = 32) among African-Americans. To investigate the consequence of this amino
acid substitution, a cDNA construct (p53 mut47ser) containing the mutation was introduced into a lung
adenocarcinoma cell line (Calu-6) that does not express p53. A growth suppression similar to that obtained after
introduction of a wild-type p53 cDNA construct was observed, in contrast to the result obtained by introduction
of p53 mutl43ala. Furthermore, expression of neither p53 mut47ser nor wild-type p53 was tolerated by growing
cells. In transient expression assays, both mut47ser and wild-type p53 activated the expression of a reporters
gene linked to a p53 binding sequence (PG13-CAT) and inhibited the expression of the luciferase gene under
the control of the Rous sarcoma virus promoter (RSVluc). In the same assay, mutl43ala did not activate the
expression of PG13-CAT and produced only a slight inhibitory effect on RSVluc. These findings indicate that
the p53 variant with a serine at codon 47 should be considered as a rare germ-line polymorphism that does not
alter the growth-suppression activity of p53.
Introduction
p53 protein plays an important role in the regulation of
cell growth. Apparently its function is dependent upon
its structure, because several mutant forms that induce
new epitopes (Finlay et al. 1988; Gannon et al. 1990)
can immortalize rodent cells in culture Uenkins et al.
1984), cooperate with the ras oncogene to transform
rodent cells in culture (Eliyahu et al. 1984; Jenkins et al.
1984; Parada et al. 1984), and cooperate with SV40 T in
the neoplastic transformation of human bronchial epi-
thelial cells (Gerwin et al. 1992). Information on the
tertiary structure of the p53 protein is not yet available,
since it has not been crystallized; however, some infer-
ences can be derived from analysis of cDNA and pro-
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tein sequences in different species (Zakut-Houri et al.
1985).
Several polymorphisms have been described for the
p53 gene (Harris et al. 1986; Matlashewski et al. 1987;
Ahuja et al. 1990; Carbone et al. 1991; Toguchida et al.
1992), but few have been characterized. The codon 72
(arg-*pro) polymorphism alters the electrophoretic mo-
bility of the protein (Harris et al. 1986). The distribu-
tion of the codon 72 polymorphism was found to differ
significantly between Caucasians and African-Ameri-
cans, and there was a tendency for the proline allele to
be overrepresented in patients with lung adenocarci-
noma (Weston et al. 1992). Very recently, the analysis
of germ-line mutations of the p53 tumor-suppressor
gene in patients with the Li-Fraumeni syndrome re-
vealed that one of seven missense mutations (codon
181, arg-*his) retained some in vitro activities of wild-
type p53 (wt p53) (Frebourg et al. 1992a, 1992b). In the
present study, using a similar functional approach, we
have characterized a new and rare p53 polymorphism at
codon 47 (CCGPro°*TCGser) by expressing a protein
with this mutation in a human lung adenocarcinoma
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cell line (Calu-6) in which p53 is not usually detected
(Caamano et al. 1991; Lehman et al. 1991). By compari-
son with experiments introducing either wt p53 or p53
mutl43ala, we have shown that the C--T substitution
in codon 47 does not appear to alter the wild-type char-
acteristics of the protein, despite the fact that 1 of the
23 proline residues in the transactivation domain is re-
placed by a serine residue.
Material and Methods
Polymorphism Detection
A PCR/restriction digest-genotyping test was devel-
oped on the basis of the abolition of an NciI restriction
site by the C--T transition at codon 47. Genomic
DNA was extracted from non-neoplastic human lung
tissues of 101 subjects obtained at autopsy from Univer-
sity of Maryland Hospital at Baltimore. DNA samples
(500 ng) were suspended in buffer (15 mM Tris pH 8.0,
50 mM KCI, 2 mM MgCl2, 0.3 mM dNTP, containing
TGAGGACCTGGTCCTCTGAC and AGAGGAATC-
CCAAAGTTCCA [0.4 jM] as 5' and 3' primers, respec-
tively) and amplified for 35 cycles (94°C for 40 s; 60°C
for 1 min; and 78°C for 30 s). The resulting PCR prod-
ucts (420 bp) were digested to completion with NciI
and analyzed by agarose gel electrophoresis.
Cell Line
Calu-6 is a lung adenocarcinoma cell line that con-
tains a termination codon at position 196 of p53 and
does not express detectable levels of p53 mRNA and
protein (Caamano et al. 1991; Lehman et al. 1991). Fur-
thermore, a karyotype analysis of the cells utilized in
this study (Children's Hospital of Michigan, Detroit)
revealed complete loss of the chromosome 17 pair, a
pattern frequently observed in the Calu-6 cell line. Cells
were grown in HUT medium (RPMI 1640, 20 mM
Hepes, 10% fetal bovine serum [FBS]) supplemented
with antibiotics.
Recombinant Plasmids
pC53-SN (i.e., wt p53), pC53-SCX3 (i.e., p53
mutl43ala), and pCMV-NEO-BAMHI (cmvneo) con-
trol vector were provided by Dr. B. Vogelstein (Johns
Hopkins University Medical Center, Baltimore). In
these constructs the p53 gene is controlled by theCMV
promoter, and the neo gene (TnS) is controlled by the
thymidine kinase promoter. Cmvneo47 was con-
structed by site-directed mutagenesis. In brief, the wt
p53 cDNA fragment was inserted into the BamHI site
of the pSelect vector (Promega), containing a nonfunc-
tional Amp R gene. A 20-bp primer harboring the de-
sired p53 mutation (5'ATATCGTCCGAGGACAG-
CAT) and a second primer which would restore Amp R
in the plasmid were annealed after single-stranded
DNA production. Plasmids were selected on the basis
of restored Amp R, as described in the Promega in-
struction manual. The reporter plasmids PG13-CAT
and MG15-CAT were also gifts of Dr. B. Vogelstein.
PG13-CAT contains 13 copies of nucleotides 103-134
from fragment A which correspond to the p53 binding
site located in the upstream region of the ribosomal
gene cluster (Kern et al. 1991). MG-15 contains a mu-
tated p53 binding site sequence which is not bound by
either wt p53 or mutant p53 proteins. Rous sarcoma
virus promoter (RSVluc) was a gift of Dr. B. Paterson
and contains the luciferase gene under the control of
Rous sarcoma virus LTR (de Wet et al. 1987).
Transfections
All transfection experiments were performed with
Calu-6 cells (between passages 52 and 60) at 80% con-
fluence in 10-cm Petri dishes. For transfection of the
p53 and CMV control constructs, 10 gg of plasmid
DNA, together with 25 jg of Lipofectin (Bethesda Re-
search Laboratories, Gaithersburg, MD), were mixed
together and then added to HUT medium without FBS
(5 ml/dish), according to manufacturer's instructions.
After 5 h, the medium was replaced by HUT medium
with 10% FBS, and selection with 75 ,ug G418/ml (ge-
neticinO; Gibco BRL) was begun 48 h after transfection.
After 14 d of selection, a mass culture (experiment 1)
and clonal subpopulations (experiment 2) were estab-
lished and expanded.
For transient expression assays, the reporter plasmids
PG13-CAT (0.75 gg) and MG15-CAT (0.75 jg) and
RSVluc (1.5 ,ug) were cotransfected with p53 expres-
sion vectors (2.5,g) by using the lipofection procedure
and Calu-6 cells, under conditions that were the same
as those described above. The CAT and luciferase activ-
ities were analyzed after 24 h, using Promega reagents
and protocols (Promega, Madison).
Southern Blot Analysis
DNA was extracted as follows: Cells were washed
once with PBS and were resuspended in lysis buffer
(200 mM NaCl, 50 mM Tris pH 7.4,0.4% SDS, 5 mM
EDTA). Proteinase K was added to a final concen-
tration of 0.1 mg/ml. Digestion (at 600C for 2 h)
was followed by phenol:chloroform:isoamylalcohol
(25:24:1) extraction, and DNA was precipitated by the
addition of 2.5 vol of ice-cold ethanol. BamHI-digested
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Table I
Ethnic Distribution of the Polymorphism at Codon 47 of p53
No. WITH ALLELE COMBINATIONS'
No. OF
SUBJECTS pro/pro pro/ser ser/ser
African-American
......... 32 29 3b 0
Caucasian American ...... 69 69 0 0
apro/pro = proline homozygote; pro/ser = heterozygote; and ser/ser = serine homozygote. The serine
allele lacks the NciI restriction site, and the proline allele contains the NciI restriction site.
b The distribution of the serine allele is significantly different (P < .05; Fisher's exact test) between
African-Americans and Caucasians.
samples were analyzed in a Southern blot hybridization
(16 h at 65"C) to the XbaI fragment of p53 cDNA (1.8
kb) that had been labeled by random priming. Blots
were washed twice at low stringency (2 X SSC, 250C),
then at increasingly stringent conditions (65°C; 2
X SSC/1% SDS, 1 X SSC/1% SDS, 0.5 X SSC/1% SDS,
and 0.5 X SSC/1% SDS).
Northern Blot Analysis
RNA was prepared from subconfluent cultures by
acid-guanidinium extraction (Chomczynski and Sacchi
1987). RNA samples (20 rg) were hybridized (16 h at
420C) to the 1.2-kb p53 coding region or the 1.5-kb rat
glyceraldehyde-phosphate dehydrogenase (GAPDH) la-
beled by random priming. Hybridized filters were
washed at 650C by following the same protocol as that
for Southern blotting.
lmmunocytochemical Analysis
Cells were seeded onto glass multiwell chamber
slides (LAB-TEK, Nunc, Naperville, IL), incubated
overnight (37°C in 3.5% CO2 at 95% humidity), and
fixed in acetone (-200C for 10 min). Endogenous per-
oxidase activity was quenched (20 min at room tempera-
ture with a 0.3% hydrogen peroxide solution in PBS).
Antigenic cross-reactivity was blocked with normal
horse serum (1:50 dilution). Saturating concentrations
of murine monoclonal primary antibodies were incu-
bated overnight at 40C and were subsequently detected
by a biotinylated secondary antibody and an avidin-
biotin peroxidase system, according to the manu-
facturer's protocol (Vecta-Stain Elite Kit; Vector
Laboratories, Burlingame, CA). The chromogen was
diaminobenzidine (final concentration 0.05 mg/ml)
with nickel chloride (final concentration 0.03%); there
was no counterstain. A proliferation marker, Ki-67,
demonstrated the viability of the cell cultures (working
dilution 1:1,000, M722; Dakopatts, Glostrup, Den-
mark). A monoclonal antibody to SV 40 large T antigen
served as an isotype-matched negative control (working
dilution 1:500, PAB 416, AB-2; Oncogene Science,
Manhasset, NY).
p53 protein accumulation was demonstrated by con-
cordant staining with multiple monoclonal antibodies,
including PAB 1801 (working dilution 1:1,000, AB-2;
Oncogene Science, Manhasset, NY), PAB 122 (working
dilution 1:300, 14091A; Pharmingen, San Diego), DO-1
(working dilution 1:1,000, provided by Dr. David P.
Lane, University of Dundee, U.K.), and BP-53-12 (work-
ing dilution 1:25, MA195-5C; Biogenex, San Ramon,
CA). Intense extranucleolar, nuclear staining was the
criterion for a positive reaction.
Amplification of the Neo Gene
The presence of the neo gene from the recombinant
plasmid was determined by PCR. DNA (200-500 ng)
isolated from the cells was suspended in a reaction
buffer (67 mM Tris-HCI pH 8.8, 6.7 mM MgCl2, 16.6
mM (NH4)2SO4, 6.8 gM EDTA, 10 mM 2-mercap-
toethanol, 1 mM dNTP) and was subjected to 35 cycles
of denaturation (40 s at 94°C), annealing (1 min at
60°C), and elongation (30 s at 78°C) in the presence of
Taq polymerase (1 U; Cetus) and neo-specific 5' and 3'
primers ACGTGAATTCGATGGATTGCACGC-
AGGTTC and CGATGGATCCGCAGGAGCAAGG-
TGAGAGATGA (1 gM each), respectively. Amplifica-
tion produced a 330-bp fragment.
Growth Rate
Growth rates were determined by plating cells in trip-
licate dishes at 103 cells/60-mm dish and staining 3
dishes/d at 24-h intervals for 8 d. Cells were rinsed in
PBS, fixed for 10 min (4% formaldehyde), and stained
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Figure I Growth rate of Calu-6 and cell lines derived from transfection of mut47ser (cl. 11 and 15) or wt p53 (cl. 19). Cells were plated in
triplicate at a density of 35 cells/cm2, and the number of cells per colony was counted in 60 colonies per line on several days between days 2
and 10.
for 5 min (0.25% crystal violet). The number of cells per
colony was determined using the Bioquant System IV
Image Analysis (R & M Biometrics, Nashville). The
number of cells was determined in 20 colonies/dish,
and population doublings (pd) are expressed as
log2(cells per colony).
Results
Distribution of p53 Alleles
The PCR analysis with restriction enzyme digestion
was performed on genomic DNA samples from 32
African-Americans and 69 Caucasians (table 1). The
overall serine allele frequency was 1.5%; however, this
allele was found only in African-Americans, and, in that
group, the frequency was 4.7% (3/64 alleles). Accord-
ing to the Hardy-Weinberg equilibrium, the frequency
of the ser/ser allele in the African-American population
would be 1/500; thus, a homozygous mutant would
not be expected to be detected in the studied popula-
tion.
Colony Formation Efficiency and Clonal Growth Rates
After introduction of wt-, mut47ser-, and mutl43ala-
p53 constructs into Calu-6, geneticin-resistant colonies
were counted 3 wk later. Calu-6 cells transfected with
pC53-SN3 (wt p53) and cmvneo47 (mut47ser) formed
35 and 8 colonies, respectively, while 108 and 167 colo-
nies were obtained in cells transfected with pC53-SCX3
(mutl43ala) and the cmvneo control vector, respec-
tively. These results indicate that both the wt p53 and
the mut47ser inhibited the clonal growth of Calu-6.
To characterize the geneticin-resistant colonies,
some were expanded into cell lines. During this process
we observed that the cell lines derived from cmvneo47
transfection (clone [Cl.] 10, 11, 14, and 15) had a lower
growth rate when compared with the clones derived
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Figure 2 Northern analysis of RNA extracted from Calu-6
cells transfected with mutl43ala p53 (Cl. 1, 4, 5, 6, 7, 8, and 9),
mut47ser (Cl. 10, 11, 14, and 15), wt p53 (Cl. 19), or control vector
(cmV). Exogenous p53 expression was determined by hybridization
with the p53 coding region (1.2 kb) and was compared with the
expression of endogenous GAPDH.
from transfection of wt p53 (Cl. 19 and 20) or
mutl43ala (Cl. 1, 4, 5, 6, 7, 8, and 9). Generally
mut47ser clones reached 28 pd 3 wk later than clones
transfected with wt p53 or mutl43ala. When mut47ser
clones (Cl. 1 lmut47 and Cl. 15mut47) were plated after
26 pd at a low clonal density, a dramatic growth sup-
pression was observed in comparison with Cl. 19wt
(fig. 1).
p53 Expression and Activity
To determine whether the observed growth pattern
correlated with p53 expression, RNA harvested after
28 pd was analyzed with a p53 probe. Four (Cl. 1, 4,5,
and 6) of seven clones derived from transfection with
mutl43ala were found to express the exogenous mes-
sage (fig. 2). In contrast, none of the clones derived
from wt p53 or mut47ser p53 expressed the exogenous
gene (fig. 2). The same result was observed in the mass
cultures derived from Calu-6-transfected cells in ex-
periment 1 (data not shown). To buttress this correla-
tion with mRNA expression, a subset of clones was
examined for p53 protein accumulation (table 2). The
untransfected Calu-6 culture had been previously
shown to lack detectable levels of p53 protein (Lehman
et al. 1991). The examined clones included one wild-
type, one mut47ser, and two mutl43ala clones. One of
the mutl43ala clones (Cl. 1) expressed p53 mRNA, and
this was the only clone to accumulate high levels of p53
protein. The remaining clones were negative for p53
mRNA, and all contained less than 3.4% positive cells.
These results complement the northern analysis results,
which would not be expected to detect mRNA from
such a small subpopulation.
To further investigate these results, DNA samples
from the cell cultures were examined for the exogenous
p53 cDNA sequence. All the p53 clones, which ex-
pressed p53 mRNA, plus clone 8, which did not ex-
Table 2
p53 mRNA and Protein in Calu-6 Cultures Transfected with Wild-Type and Mutant p53
Constructs
PROTEIN ACCUMULATIONb
TRANSFECTED P53 No. of Positive Cells/
CONSTRUCT CULTURE TYPE MRNAa % of Positive Nuclei Total
None .......... Mass culture -c 0 N/A
Wild type ....... Clone 19 - 3.4 15/435
Mut47ser ....... Clone 11 - <.1 N/A
Mutl43ala ...... Clone 1 + 64.5 240/372
Mutl43ala ...... Clone 7 - 1.8 8/435
a p53 mRNA detected by northern blot; a minus sign indicates absence, and a plus sign indicates
presence.
b Quantitation of p53 protein accumulation was performed by manual counts of sequential cells. Three
staining categories were identified: cells with intense nuclear, extranucleolar staining are positive; cells with
negative nuclei are negative; and cells with faintly stained nuclei with or without cytoplasmic staining are
intermediate (+/-); fragmented and mitotic cells were not counted. The ratios (e.g., 15/435) are no. of
positive cells/no. of positive plus negative cells (i.e., the +/- negative nuclei are excluded). All ratios are
composed of two independent experiments. N/A = not applicable. The percentage of positive nuclei was
calculated excluding the +/- nuclei.
' Caamano et al. 1991; Lehman et al. 1991.
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sion results, mut47ser showed a transactivation of the
PG13-CAT construct similar to that of wt p53, whereas
mutl43ala was totally ineffective (table 3). Luciferase
activity was analyzed with the initial purpose of
correcting for transfection efficiency. In the presence
of wt p53 or mut47ser p53, only 30% of the luciferase
activity was observed, in comparison with the result
obtained with the control vector (table 3). The lucifer-
ase activity was also slightly decreased in the presence
of mutl43ala.
Discussion
mut 143AIa mut 47Ser wt
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In this study we report that a mutation at codon 47
of p53 (CCGPro°-)TCGSer), originally described in bron-
chial epithelial cells immortalized by the SV40 large T
antigen and the donor's cells (Gerwin et al. 1992), is
actually a rare p53 germ-line polymorphism that does
not appear to alter the function of the protein. The
allelic frequency of mut47ser p53 is 0% in the Cauca-
sian population and 4.7% in the African-American pop-
ulation, which is less than the codon 72 arg/pro poly-
morphism that occurs in 35% of the population (de la
Calle-Martin et al. 1990; Weston et al. 1992). Inherited
forms of p53 mutations have been described in families
Figure 3 a, Southern analysis of DNA extracted from Calu-6
cells transfected with mutl43ala (Cl. 1, 4, 5, 6, 7, and 8), mut47ser
(Cl. 10, 11, 14, and 15), or wt p53 (Cl. 19 and 20). The presence of the
exogenous p53 was determined in BamHI-digested genomic DNA.
Intact exogenous p53 has a size of 1.8 kb. b, Detection of the neo
gene by PCR analysis in DNA extracted from Calu-6 cells transfected
with mutl43ala (Cl. 1, 4,5,6,7, and 8), mut47ser (Cl. 10, 11, 14, and
15), or wt p53 (Cl. 19 and 20). Aliquots of the PCR products were
electrophoresed on 4% NuSieve-agarose gels and stained with ethi-
dium bromide. The first lane contains Gelmarker I (molecular weight
1,000, 700, 500, 400, 300, 200, 100, and 50 bp).
press p53 mRNA, contained an intact copy of the exog-
enous p53 construct (fig. 3a). However in clone 7
(mutl43ala) and in all four clones from mut47ser, the
exogenous p53 sequences were deleted or rearranged
(fig. 3a). In contrast, the exogenous p53 gene was also
intact in both wild-type-derived clones; these two
clones also showed an unidentified band of high-mole-
cular-weight DNA hybridizing with the p53 probe. All
of the clones contained the neo gene (fig. 3b). Thus,
both mut47ser and wt p53 were inactivated, although
by different mechanisms.
To evaluate the activities of the different p53 vectors
as transcription modulators, transient expression assays
were performed. In agreement with the stable expres-
Table 3
Transcriptional Activity of Exogenous p53 Proteins
Detected in Transient Expression Assays
Reporter Plasmid and Expression
Plasmid %a
PG13-CAT:
cmvneo .......................... 0
wt p53 .......................... 7.6 ± 3.1
mut47ser .......................... 9.2 ± 6.2
mutl43ala ......................... 0
MG15-CAT:
wt p53 .......................... 0
RSVluc:
cmvneo .......................... 100
wt p53 ........................ 30.8 ± 14.7
mut47ser ........................ 24.8 ± 9.5
mutl43ala ........................ 48.9-89.2b
a PG13-CAT (0.75 jig) or MG15-CAT (0.75 jig) and RSVluc (1.5
jg) were cotransfected with p53 expression vectors (2.5 jg) into
Calu-6 cells. The CAT and luciferase activities of transfected cells
were analyzed 24 h after the transfection. The CAT activity is ex-
pressed as a percent of 14C-chloramphenicol conversion. The lucifer-
ase activity is expressed relative to that obtained with RSVluc and
cmvneo (i.e., 100%). Values are expressed as mean ± SD for n = 4.
b Range obtained in three independent experiments.
a
23-
9-6.6-
4.5-
2.3-
2.0-
b
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with Li-Fraumeni syndrome (Malkin et al. 1990), in pa-
tients with two independently arising neoplasms (Mal-
kin et al. 1992), and in patients with sarcomas (Togu-
chida et al. 1992), but not every germ-line mutation was
associated with tumor development in a cancer-prone
family (Frebourg et al. 1992a).
Functional analysis of the p53 with a serine at codon
47 was performed by introduction of a cDNA contain-
ing this polymorphism (mut47ser) into Calu-6 cells, a
lung adenocarcinoma cell line that does not express
p53 (Caamano et al. 1991; Lehman et al. 1991). The
results indicate that mut47ser protein maintains similar
growth-suppression capacity and transcription-transac-
tivation activity as that of the wt p53 construct. Calu-6
cells could not tolerate the expression of either
mut47ser or wt p53 during their growth. This result is
similar to that obtained by introduction of wt p53 in
NCI-H358 lung bronchoalveolar carcinoma, which car-
ries a homozygous deletion at the p53 locus (Takahashi
et al. 1992).
Four of seven lines derived from transfection with
the construct containing the mutl43ala were found to
express the exogenous p53. This is consistent with re-
sults expected in human cells transfected with a vector
containing two independent transcription units (Baker
et al. 1990 and references therein). In some of the
clones the expression of integrated p53 gene was re-
stricted; this had already been observed in the K562
CML cell line and in SKOV-3 ovarian adenocarcinoma
(Johnson et al. 1991), and the mechanism remains ob-
scure.
The transactivation of PG13-CAT, which contains
multiple copies of the p53 binding sequence, by p53
mut47ser demonstrated that this mutant retained wild-
type activity (Kern et al. 1991; Frebourg et al. 1992a,
1992b) in this assay. A similar result was observed with
the codon 181 his mutant p53 transfected into Saos-2
cells (Frebourg et al. 1992a). This is in contrast with
mutl43ala, which was completely unable to bind the
PG sequence. Furthermore wt and mut47ser inhibited
luciferase expression to the same extent (70%); this re-
porter expression is under the control of the Rous sar-
coma virus LTR promoter which was recently shown to
be down regulated by wt p53 in Hela cells (Subler et al.
1992). This is consistent with the inhibitory effect of wt
p53 on several cellular promoters (Ginsberg et al. 1991;
Santhanam et al. 1991; Agoff et al. 1993). Therefore,
the p53 gene is shown to both transactivate and inhibit
gene expression in the same experiment and highlights
the difficulty in establishing an appropriate control for
the evaluation of transfection efficiency. Nevertheless,
the reproducibility of the results attests to the reliability
of the data.
Several rare polymorphisms in the N-terminus of p53
(codons 11, 21, 31, and 49) have been recently de-
scribed (Ahuja et al. 1990; Toguchida et al. 1992). The
phenotypic consequences of these variants are not
known.
In this study we show that replacing one of the pro-
line residues in the "proline stretch" by a serine has no
demonstrable effect on the ability of p53 to suppress
growth and control transcription. Even though we can-
not exclude that this polymorphism alters unexamined
properties, mut47ser functioned as wt p53 in our
model system.
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